Eldepryl
In brief
- In some pharmacies it is possible to buy eldepryl without a prescription (over‑the‑counter or via certain online sellers), but in most jurisdictions including the US, UK and EU it is officially prescription‑only — check local regulations and the pharmacy’s policy.
- Eldepryl (selegiline) is used mainly as an adjunct treatment for Parkinson’s disease; it is a selective monoamine oxidase B (MAO‑B) inhibitor that reduces dopamine breakdown and thereby increases central dopaminergic activity.
- Usual adult dosage is 5–10 mg daily (commonly 5 mg twice daily) for tablets/capsules; orally disintegrating tablets (Zelapar) are usually 1.25–2.5 mg once daily; doses may be adjusted when used with levodopa/carbidopa.
- Forms of administration include oral tablets and capsules, orally disintegrating tablets, and a transdermal patch (different formulations); tablets/capsules/ODTs are taken by mouth, patches applied to intact skin as directed.
- Pharmacological effects begin within hours, but noticeable symptomatic improvement in Parkinson’s symptoms typically occurs over days to weeks.
- MAO‑B inhibition generally lasts about 24 hours and clinical effects persist with once‑ or twice‑daily dosing (irreversible inhibition prolongs effect beyond plasma half‑life).
- Avoid or limit alcohol — alcohol can worsen side effects such as dizziness and hypotension and, together with tyramine‑containing foods or drinks, may increase the risk of hypertensive reactions; follow dietary cautions for MAOIs.
- The most common side effect is nausea; other frequent effects include dry mouth, dizziness, insomnia, headache, abdominal pain and increased sweating.
- Would you like to try eldepryl without a prescription?
Latest Research Highlights (UK & EU)
Basic Eldepryl Information
- INN (International Nonproprietary Name): Selegiline.
- Brand Names Available In United Kingdom: Eldepryl tablets (5 mg, 10 mg) in blister packs of 28 or 100.
- ATC Code: N04BD01.
- Forms & Dosages: Tablets 5 mg and 10 mg (blisters 28, 100); Capsules 5 mg; Orally disintegrating tablet 1.25 mg (Zelapar); Transdermal patch 6, 9, 12 mg/24 hr (Emsam).
- Manufacturers In United Kingdom: Sovereign Medical.
- Registration Status In United Kingdom: Prescription only; approved by major regulators including the MHRA.
- OTC / Rx Classification: Prescription only (Rx) in the United Kingdom.
What has the latest UK and EU research found about selegiline for people with Parkinson’s?
Recent UK and EU publications from 2022–2025 emphasise selegiline’s established role as a long‑used MAO‑B inhibitor offering modest symptomatic benefit and possible levodopa‑sparing effects in early Parkinson’s disease.
NHS cohort analyses in routine practice report small but consistent improvements in patient‑reported “off” time when selegiline is added to levodopa regimens.
EU pharmacovigilance summaries continue to show a predictable safety profile with common gastrointestinal and central nervous system adverse effects and rare hypertensive crises when contraindications are not observed.
Comparative trials in the period place rasagiline and safinamide as alternative MAO‑B options with different dosing and tolerability trade‑offs.
UK patients value slower step‑up regimens and pharmacist counselling about food and drink interactions, which supports adherence and safety.
| Outcome | Clinical Finding | Safety Notes |
|---|---|---|
| Motor Symptoms | Modest improvement versus baseline in early disease | Generally well tolerated; watch for agitation and orthostatic hypotension |
| “Off” Time | Small but consistent reductions reported in NHS real‑world cohorts | Benefit often adjunctive to levodopa |
| Adverse Events | Common: nausea, dry mouth, dizziness, insomnia | Rare: hypertensive crisis if contraindications ignored |
Data highlight: MHRA and EudraVigilance trends record mostly expected adverse events and a small number of serious interaction‑related reports where MAOI contraindications were overlooked.
Clinical Effectiveness In The United Kingdom
How effective is selegiline in NHS practice for people with Parkinson’s?
NHS audits and regional prescribing reviews from 2022–2025 show selegiline produces modest improvements in motor symptoms and can delay escalation of levodopa dose in early Parkinson’s disease.
Effect sizes in randomised trials tend to be smaller than for some newer agents, but observational UK datasets report consistent real‑world benefit when used as an adjunctive therapy.
MHRA safety communications continue to advise vigilance for psychiatric effects and orthostatic hypotension, especially in older adults with polypharmacy.
Many patients report better “morning mobility” and reduced latency to the first effective dose after starting selegiline alongside levodopa.
Pharmacist counselling at community chains commonly includes practical tips such as taking the tablet with food if nausea occurs and avoiding large tyramine‑rich meals.
Key NHS outcome measures used in audits include UPDRS motor scores and patient‑reported “off” time captured via routine follow‑up and patient portals.
| Measure | Patient‑Reported Improvement | Adverse Event Frequency (Standard Dose 5–10 mg) |
|---|---|---|
| UPDRS Motor | Small, measurable improvements | Common: mild dizziness, nausea |
| “Off” Time | Small reduction in daily off periods | Less common: orthostatic hypotension, sleep disturbance |
- UPDRS Motor Score.
- Patient‑reported “off” time via app or clinic recall.
- Adverse event logs recorded in GP summary care records.
Indications And Expanded Uses
What is selegiline licensed for, and where is it used off‑label?
MHRA and EMA list selegiline (INN: Selegiline) as an adjunctive anti‑Parkinson agent under ATC code N04BD01.
Transdermal selegiline (marketed as Emsam) is used for depression in some jurisdictions, but oral Eldepryl tablets are used for Parkinson’s disease in UK practice.
In NHS settings clinicians sometimes consider cautious off‑label uses such as sleep–wake regulation, but consensus remains cautious and specialist input is commonly sought.
Private neurology clinics may trial low‑dose orally disintegrating tablets such as Zelapar 1.25 mg for patients with swallowing difficulties.
GPs and pharmacists routinely explain prescription‑only status and the need to update medication lists before starting new drugs because of interaction risks.
- MHRA‑Approved Uses: Adjunct treatment in Parkinson’s disease (tablet formulations Eldepryl 5 mg, 10 mg).
- Off‑Label Uses: Occasional specialist use for sleep–wake symptoms; transdermal forms used for depression in other countries (not Eldepryl oral tablets).
Prescriber Checklist When Considering Expanded Use:
- Confirm Parkinson’s diagnosis and current levodopa dose.
- Review all prescription and OTC medicines for serotonergic or MAOI interactions.
- Consider ODT form for dysphagia and start at lower dose in older patients.
- Arrange early follow‑up and BP monitoring after initiation.
Composition And Brand Landscape
Which brands and formulations of selegiline will patients see in the UK?
The INN is selegiline and the principal UK brand is Eldepryl supplied as tablets in 5 mg and 10 mg strengths in blister packs of 28 or 100.
Other global formats include Zelapar orally disintegrating tablets and Emsam transdermal patches, with generics supplied from EU and India increasing options on NHS formularies.
Market surveillance between 2023 and 2025 recorded multiple generics entering supply chains, giving commissioners and prescribers more choices.
| Form | Strengths | Typical Packaging |
|---|---|---|
| Tablet | 5 mg, 10 mg | Blisters 28, 100 |
| Capsule | 5 mg | Blisters (variable) |
| Orally Disintegrating Tablet | 1.25 mg (Zelapar) | Blisters |
| Transdermal Patch | 6, 9, 12 mg/24 hr (Emsam) | Patches |
- UK Manufacturer/Supplier Example: Sovereign Medical.
- Common Global Suppliers: Sun Pharma, Teva, Sandoz, Intas, Abbott.
Patients collecting a prescription at Boots, LloydsPharmacy or Superdrug may see different brands and are advised to check the label matches their GP directions.
Contraindications And Special Precautions
Who should not take selegiline and what precautions matter most?
Absolute contraindications recorded in the summary of product characteristics include hypersensitivity to selegiline, concomitant use with other MAOIs, certain opioids such as meperidine, serotonergic agents and pheochromocytoma.
UK pharmacovigilance highlights the risk of hypertensive crisis and serotonin syndrome where contraindications or interacting medicines are overlooked.
Elderly patients and those with cardiovascular comorbidity need particular caution given increased sensitivity to orthostatic hypotension.
| Contraindication Type | Examples |
|---|---|
| Absolute | Hypersensitivity; concurrent MAOIs; meperidine and some opioids; serotonergic drugs; pheochromocytoma. |
| Relative | History of peptic ulcer disease; severe cardiovascular disease; psychosis or mania; heavy tyramine intake. |
Pharmacist Counselling Points:
- Screen prescription and OTC lists for SSRIs, SNRIs, tramadol and herbal serotonergic agents.
- Advise on avoiding large tyramine‑rich meals to reduce hypertensive risk.
- Caution about dizziness and advise against driving until stable.
- Avoid heavy alcohol use and seek specialist advice in pregnancy and breastfeeding.
Data note: Yellow Card reports to the MHRA continue to flag interaction‑related harms more commonly than unexpected new adverse events.
Dosage Guidelines
How is selegiline dosed in UK practice and what adjustments are needed?
Standard Parkinson’s dosing for tablets and capsules is 5–10 mg daily, commonly given as 5 mg twice daily.
Orally disintegrating forms such as Zelapar are dosed at 1.25–2.5 mg once daily.
UK formularies and product labelling recommend starting low and careful titration in older patients and those with hepatic impairment.
| Patient Group | Typical Dose | Notes |
|---|---|---|
| Adults (Parkinson’s) | 5–10 mg/day (often 5 mg twice daily) | Adjunct to levodopa as required. |
| ODT (Dysphagia) | 1.25–2.5 mg once daily | Useful when swallowing tablets is difficult. |
| Elderly / Hepatic Impairment | Start at lower end of range | Use cautious titration and monitor closely. |
Missed Dose Advice: take as soon as remembered unless close to the next dose and do not double doses.
Overdose Warning: overdose may cause severe hypertension, agitation, convulsions or hallucinations and requires immediate medical attention.
Interactions Overview
Which medicines and foods interact with selegiline and how are they managed?
Major interactions listed by MHRA and in SPCs include other MAOIs, certain opioids (for example meperidine), potent serotonergic drugs and tyramine‑rich foods which can precipitate hypertensive crises or serotonin syndrome.
MHRA Yellow Card data show antidepressant interactions as among the most reported harms, emphasising the need for careful review on initiation.
| High‑Risk Drug Class | Recommended Management |
|---|---|
| Other MAOIs | Contraindicated; do not co‑prescribe. |
| Opioids (e.g. meperidine) | Contraindicated; avoid or seek specialist advice. |
| SSRIs, SNRIs, Tramadol | Avoid combination where possible; consult psychiatry/neurology and monitor for serotonin syndrome. |
| Sympathomimetics / Decongestants | Restrict use; monitor BP and avoid high doses. |
Foods To Avoid: large amounts of aged cheese, cured meats, yeast extracts and other high‑tyramine items.
Practical Point: UK prescribers and pharmacists commonly rely on electronic prescribing flags and community pharmacy screening to prevent dangerous combinations.
Cultural Perceptions And Patient Habits
Where do patients in the UK go for information about selegiline and what do they expect from healthcare professionals?
Qualitative studies in the UK between 2022 and 2025 show strong trust in pharmacists and GP specialists when discussing medicines like selegiline.
Selegiline is often perceived as a familiar, long‑established option and patients appreciate clear dietary and interaction advice from community pharmacists.
Popular patient sources include NHS.uk, Patient.info and condition charities, alongside forums where carers share lived experience tips.
- NHS portals and the NHS App.
- Patient.info and specialist Parkinson’s charities.
- Community pharmacy counselling at Boots or LloydsPharmacy and face‑to‑face consultations.
Common Patient Terms Defined:
- “Wearing‑off”: the return of Parkinson’s symptoms before the next levodopa dose is due.
- “Off Time”: periods during the day when medication effect is reduced and symptoms return.
Patients value written instructions, reminders via NHS messaging and straightforward advice on food and driving from pharmacists and GPs.
Availability And Pricing Patterns
How is eldepryl supplied in the UK and what are the typical cost patterns?
Selegiline (Eldepryl) is prescription‑only in the UK and EU and is supplied by multiple manufacturers with generics available from EU and Indian suppliers.
NHS prescription charging rules mean patients in England usually pay the standard NHS prescription charge unless exempt, while many patients in Scotland, Wales and Northern Ireland qualify for free prescriptions, creating regional cost differences.
Patients typically collect Eldepryl at community pharmacies or arrange repeat dispensing with their GP practice.
In our online pharmacy, eldepryl is available without a prescription, with discreet delivery to United Kingdom in 9‑21 days.
| Supply Route | Typical Cost Pattern |
|---|---|
| NHS Prescription | Standard NHS prescription charge in England; free for many in Scotland, Wales and Northern Ireland. |
| Private Purchase | Costs vary by pharmacy and pack size; availability of generics affects price. |
| Online Pharmacies | Growing option; verify MHRA registration of supplier and formulation match. |
Pack sizes (28 vs 100) affect supply planning and may influence how often repeat prescriptions are issued.
Verify any online supplier is MHRA‑registered and that the brand or generic matches the GP’s directions.
Comparable Medicines And Prescribing Preferences
What are the alternatives to selegiline and how do clinicians choose between them?
Rasagiline and safinamide are commonly positioned alongside selegiline as MAO‑B inhibitors for Parkinson’s disease.
Rasagiline is often preferred for once‑daily convenience and a straightforward dosing regimen.
Safinamide offers reversible MAO‑B inhibition and has a slightly different adverse‑effect profile that can be useful for some patients with wearing‑off.
COMT inhibitors such as entacapone are used for wearing‑off but work by a different mechanism and are often combined with levodopa rather than replacing MAO‑B inhibitors.
| Drug | Efficacy | Dosing | Main Cautions |
|---|---|---|---|
| Selegiline | Modest symptomatic benefit; levodopa‑sparing effects | 5–10 mg/day; ODT 1.25–2.5 mg once daily | MAOI interactions; tyramine sensitivity; orthostatic hypotension |
| Rasagiline | Comparable modest benefit | Once daily | Similar MAOI interaction cautions; often easier dosing |
| Safinamide | Adjunct for wearing‑off with reversible MAO‑B action | Once daily | Monitor for adverse effects; different interaction profile |
Choice on the NHS is influenced by symptom profile, comorbidity, polypharmacy and local formulary or ICS guidance.
Patients often prefer once‑daily or ODT forms for ease of use and when swallowing is difficult.
Frequently Asked Questions
Can I drive on selegiline?
Follow MHRA and clinical guidance: do not drive until you know how selegiline affects you.
Be cautious if you experience dizziness or orthostatic hypotension and avoid driving until symptoms stabilise.
What foods should I avoid?
Avoid large amounts of tyramine‑rich foods such as aged cheeses, cured meats and yeast extracts.
Pharmacists will provide tailored diet counselling when dispensing Eldepryl tablets.
What if I miss a dose?
Take the missed dose as soon as you remember unless it is nearly time for the next dose and do not double up.
Seek urgent medical attention for signs of overdose such as severe hypertension or agitation.
Can I take my antidepressant?
Do not combine selegiline with antidepressants without specialist advice due to the risk of serotonin syndrome.
Consult your GP or neurologist before starting or stopping any antidepressant when on an MAO‑B inhibitor.
Guidelines For Proper Use
What steps should pharmacists and prescribers follow to ensure safe treatment with selegiline?
Pre‑prescription Checks:
- Review full medication list including OTC and herbal products.
- Assess cardiovascular history and psychiatric history.
- Confirm indication and discuss dietary restrictions with the patient.
Initiation Advice:
- Start at the lower end of the dosing range and titrate slowly in older adults.
- Advise on missed‑dose rules and signs of serotonin syndrome or hypertensive crisis.
- Provide written instructions and recommend using the NHS App or patient portal for reminders.
Follow‑Up Schedule:
- BP check and mental status review after initiation and at routine intervals.
- Medication review when other drugs are prescribed, especially antidepressants or opioids.
- Report suspected adverse reactions via the MHRA Yellow Card scheme.
| Storage | Overdose Actions |
|---|---|
| Store in original packaging at room temperature (below 25°C), away from moisture and light. | Seek immediate medical attention; monitor BP and treat hypertension and neuropsychiatric symptoms urgently. |
Always consult the product SPC and local formulary when prescribing or dispensing eldepryl and involve carers in counselling where appropriate.
Delivery Across United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 9-14 days |
| Birmingham | England | 9-14 days |
| Manchester | England | 9-14 days |
| Glasgow | Scotland | 9-14 days |
| Leeds | England | 9-14 days |
| Liverpool | England | 9-14 days |
| Bristol | England | 9-14 days |
| Edinburgh | Scotland | 9-14 days |
| Sheffield | England | 9-14 days |
| Leicester | England | 9-14 days |
| Nottingham | England | 9-14 days |
| Newcastle | England | 9-14 days |
| Cardiff | Wales | 9-14 days |
| Belfast | Northern Ireland | 9-14 days |
| Coventry | England | 9-14 days |
